2025 Year in Review: Life Sciences Licensing & Collaboration Deals

Key Take-Away:

2025 data reflects a rebalancing of risk and capital allocation in early-stage licensing & collaboration deals, with proportionately more value being allocated earlier in development and modest compression in back-end economics.

• Median total deal value for early-stage deals increased modestly, with a larger share of value allocated to upfront and development milestone payments.

Trends in Life Sciences Licensing & Collaboration Deals:

1. Median Deal Value Increased to $470M in 2025 from $460M in 2024 for early-stage deals², and the composition shifted earlier in the development lifecycle:

• Upfront Payments more than doubled as a percent of overall deal value for early-stage deals from 1.5% to 3.7%.
• 10 percentage point increase in median development milestone payments from 23% to 33% (see chart below).
• Sales milestones still made up the majority of total deal value, but overall percentage declined from 73% to 64%.

2. Royalty tiers compressed across both early- and later-stage deals (see charts below):

• Early-Stage Deals
  • Median Low Rate Tier: 4.5% (-.5% from 2024)
  • Median High Rate Tier: 8% (-2%)
• Later-Stage Deals³
• Median Low Rate Tier: 9.3% (-.7%)
• Median High Rate Tier: 13% (-2%)

3. Equity grants by licensees remained selective (22% of deals), suggesting they were used strategically in targeted collaborations.

• For those deals with an equity grant, the median amount was 20%.

4. Consistent with 2024, 17% of deals included an opt-in, with an option as the predominant mechanism.

5. Control allocation continued to favor licensees, with licensees typically having the first right to prosecute & enforce (66% and 74% of deals respectively).